When is tirzepatide going generic?

The U.S. patent expiry for tirzepatide is anticipated in 2036 [1]. This date could shift due to potential patent challenges or extensions [2].

Will Tirzepatide Lose Exclusivity Before 2036?

While the primary patent for tirzepatide is set to expire in 2036, other intellectual property, such as method-of-use patents, could extend market exclusivity for specific indications beyond this date [1][3]. These secondary patents are often crucial for maintaining market protection even after core compound patents expire [2].

How Do Patent Expiries Affect Drug Pricing?

Upon patent expiry, the market typically opens to generic competition, which can lead to significant price reductions [4]. The introduction of generic versions of tirzepatide would likely follow a similar pattern, making the drug more accessible [2].

Who Manufactures Tirzepatide?

Tirzepatide is manufactured by Eli Lilly and Company [5].

What Are the Next Steps for Tirzepatide's Market Status?

The period leading up to the patent expiry will likely involve monitoring for any Paragraph IV patent certifications filed by potential generic manufacturers. These filings can trigger patent litigation and potentially accelerate the generic entry date [2]. The specific timeline for generic tirzepatide will depend on the outcome of these legal and regulatory processes [3].